Open an account Help & support Register Account summary Log out
Skip Header
Home Stock market news

Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Indivior CUD study fails to meet primary and secondary endpoints

Wed 04 Sep 2024 08:53

(Sharecast News) - Drugmaker Indivior said on Wednesday that the primary and secondary endpoints of Aelis Farma's clinical Phase 2B study of AEF0117 use in participants with cannabis use disorder had not been met. Indivior said the purpose of the trial was twofold - to show that AEF0117 lowers cannabis use and to determine the endpoints and optimal dosage of AEF0117 for use in future studies.

However, the London-listed group stated the results of the study demonstrated that the primary endpoint, the proportion of participants who reduced their cannabis use to less than one day per week, as well as secondary endpoints measuring the proportion of participants reaching either complete abstinence or who used less than two days per week, were not met.

"Although these results are disappointing, they indicate that significant work remains to be done to understand subpopulations of patients with CUD, specifically those with severe CUD," said Indivior.

"Given the lack of separation from placebo on primary and secondary endpoints and before seeing further additional favourable clinical data, Indivior does not currently expect to exercise its option."

As of 0850 BST, Indivior shares were down 1.86% at 896.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Mon 07 Sep 2026 08:45
The Works raises FY profit guidance as strong early‑year trading boosts momentum
(Sharecast News) - Stationery retailer The Works said on Monday that trading had continued to build momentum in the opening weeks of its new financial year, prompting it to lift profit expectations after a strong start.
Fri 24 Jul 2026 09:11
Wise to reapply for US trust-bank charter after OCC rejection
(Sharecast News) - Fintech group Wise said on Friday that the US Office of the Comptroller of the Currency had denied its application for a national trust bank charter, noting the decision relates to issues in its original submission more than a year ago.
Mon 29 Jun 2026 14:00
Smiths News inks distribution contract with Associated Newspapers
(Sharecast News) - Print media distributor Smiths News has secured a new long‑term distribution contract with Associated Newspapers, publisher of the Daily Mail, The Mail on Sunday and i.
Thu 04 Jun 2026 08:30
S4 Capital flags tough trading amid volatile macro conditions
(Sharecast News) - Digital advertising and marketing firm S4 Capital said on Thursday that trading through 2025 had continued to reflect volatile macro conditions, with tariff negotiations and geopolitical risks keeping clients cautious.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Awards

Award 1
Award 2
Award 3

Policies and important information

Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statements | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Statutory and Regulatory disclosures | Whistleblowing programme

Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.

This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.

© FIL Limited 2026